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Abstract
High-risk human papillomavirus (HPV) infection is an essential factor for the development of cervical cancer. HPV18
is the second most common carcinogenic HPV type following HPV16, but the lineages of HPV18 have been less
well studied than those of HPV 16. The purpose of this study was to analyze the nucleotide variants in the E6, E7,
and L1 genes of HPV18, to assess the prevalence of HPV18 variants in Korea and to explore the relationship
between HPV18 genetic variants and the risk for cervical cancer.
A total of 170 DNA samples from HPV18-positive cervical specimens were collected from women admitted to a
secondary referral hospital located in Seoul. Among them, the lineages of the 97 samples could be successfully
determined by historical nomenclature.
All the studied HPV 18 variants were lineage A. Sublineages A1 and A4 comprised 91.7% (89/97) and 1.0% (1/97),
respectively. Sublineages other than A1 or A4 comprised 7.2% (7/97). We identified 15 new nucleotide substitutions
among 44 nucleotide substitutions: C158T, T317G, T443G, A560G, A5467G, A5560C, A5678C, A6155G, G6462A,
T6650G, G6701A, T6809C, A6823G, T6941C and T6953C. Among them, 6 substitutions at positions 317, 443, 5467,
5560, 6462, and 6823 resulted in amino acid changes (E6: F71L and N113K; L1: H13R, H44P, A345T, and N465S,
respectively). The pathologic results were classified as normal in 25.8% (25/97) of the women, atypical squamous
cells of undermined significance (ASCUS) in 7.2% (7/97), cervical intraepithelial neoplasia (CIN) 1 in 36.1% (35/97),
CIN2/3 in 19.6% (18/97), and carcinoma in 12.4% (12/97). There was no significant association between the HPV18
sublineages and the severity of pathologic lesion or the disease progression.
This study is the first to analyze the distribution of HPV18 variants in Korean and to associate the results with
pathologic findings. Although the HPV18 variants had no significant effect on the degree and progression of the
disease, the newly discovered nonsynonymous mutation in L1 might serve as a database to determine vaccine
efficacy in Korean women.
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Introduction
Cervical cancer is the fourth most common cancer
among all malignancies in females worldwide and the
seventh most common cancer in Korea. According to
the World Health Organization’s (WHO’s) GLOBOCAN
project in 2018, 569,847 new cases occur and 311,365
people die annually due to cervical cancer worldwide. In
Korea, cervical cancer is the seventh most common can-
cer, with the development of 3348 new cases and 1029
deaths reported annually [1]. Epidemiologic, genetic, im-
munological and environmental factors are involved in
carcinogenesis, and persistent and high-risk human pap-
illomavirus (HPV) infection is an essential factor for the
development of cervical cancer. The most deleterious
type is HPV16, and the second is HPV18; these two in-
fections are associated with approximately 70% of cer-
vical cancers [2, 3].
HPV is a small double-stranded DNA virus with an 8-
kb genome containing early expressed genes (E1, E2, E4,
E5, E6, and E7), late genes (L1 and L2) and a long control
region (LCR) [4]. The capsid proteins L1 and L2 play crit-
ical roles in viral structure formation and the infection
process. In particular, purified L1, the major capsid pro-
tein, can form empty shells that resemble HPV, which are
called virus-like particles (VLPs). These VLPs have hyper-
variable immunodominant loop structures on the surfaces
of the virions that induce humoral immunity without
oncogenic activity and are thus extensively used in HPV
prophylactic vaccines [5–8]. E6 and E7 are major onco-
genes that are highly expressed in tumors and are related
to cellular immortalization, malignant transformation, and
carcinogenesis. Based on these roles, proteins E6 and E7
are generally regarded as ideal targets for the development
of therapeutic HPV vaccines [6, 9].
Over 200 HPV types have been identified based on L1
sequences. HPV18 variants were originally grouped into
European (E), Asian-Amerindian (AA) or African (AFR)
lineages according to E6-E7, L1, and/or LCR sequences
[10–14]. This classification has been superseded by a
whole viral genome sequencing approach that has de-
fined three major lineages (A, B, and C) and additional
sublineages (A1 to A5 and B1 to B3) [15] that can be
translated from the historical nomenclature (A1 and A2
are AA, A3 to A5 are E and B/C are AFR) [16, 17]. In
addition, a recent study published in China proposed
new A6 to A8 sublineages and classified them as the E
lineage [18].
HPV genetic variants have been reported to differ in
their viral assembly, pathogenic potential, and host im-
mune response depending on geographic and ethnic fea-
tures [2, 17–20]; however, no data on HPV18 variation
among strains from Korean women have been reported
thus far. Furthermore, there is some debate regarding
the carcinogenic properties of HPV18 lineages [16–24].
Methods
From 2010 to 2017, 7992 women admitted to the Seoul
National University Boramae Medical Center were tested
for cervical HPV genotype more than once. Among
them, 3926 (3926/7992 = 49.1%) were positive for HPV,
and 170 (170/3926 = 4.3%) were positive for type 18 and
negative for other types. HPV detection and typing were
performed using a liquid bead microarray, namely, the
GeneFinder HPV PCR Kit (Infopia, Seoul, Korea).
Amplification and sequencing of HPV18 E6, E7, and
L1 genes were performed using type-specific primers,
which are shown in Table 1 [11, 24, 25]. The cycling
conditions were as follows: 5 min at 95 °C for initial de-
naturation; 45 s at 94 °C, 45 s at 55 °C, and 60 s at 72 °C
for 35 cycles; and 10min at 72 °C for final elongation.
Amplicons were visualized on 2.0% agarose gels stained
with ethidium bromide under UV transillumination.
PCR products were automatically sequenced using the
BigDye Terminator v3.1 Cycle Sequencing Kit (Applied
Biosystems, Foster City, CA, USA) and an ABI 3730xl
DNA analyzer (Applied Biosystems, Foster City, CA,
USA) according to the manufacturer’s instructions. E7
sequencing had a high success rate (165/170), so the se-
quencing was completed with only 1 primer set (=1
trial). However, E6 and L1 sequencing had low success
rates, so we attempted 3 trials each (Table 1). All data
were confirmed by repeating the PCR amplification and
sequence analysis at least twice.
Nucleotide sequences were translated by the translate-
tool of ExPASy (http://web.expasy.org/translate/) for the
determination of amino acid changes. PSIPRED v.4.0
(http://bioinf.cs.ucl.ac.uk/psipred/) was used for second-
ary structure prediction, as it provides a simple and ac-
curate secondary structure prediction method.
All sequence data were assembled against the HPV18
reference strain, GenBank sequence NC_001357, using
Sequencher version 5.2.3 (Gene Codes Corporation, Ann
Arbor, MI, USA). Twenty-eight other sequences were
downloaded from GenBank, as in the latest Taizhou area
study [18]. The accession numbers used in this analysis
were as follows. A1 sublineage: EF202143-EF202145, A2
sublineage: EF202146, A3 sublineage: EF202147-
EF202149, A4 sublineage: EF202150-EF202151, A5
sublineage: GQ180787, A6 sublineage: KY457833-
KY457836, A7 sublineage: KY45737-KY45840, A8 subli-
neage: KY457826-KY457827; B1 sublineage: EF202153-
EF202155, B2 sublineage: KC470224-KC470225, B3 sub-
lineage: EF202152; and C lineage: KC470229-KC470230.
Evolutionary analyses were conducted in MEGA X
(http://megasoftware.net) [22, 23].
Based on cytological and histological evaluations of
fresh specimens, the cervical lesions were graded accord-
ing to their severity as follows: normal, atypical squa-
mous cells of undetermined significance (ASCUS), low-
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grade squamous intraepithelial lesion (LSIL), high-grade
squamous intraepithelial lesion (HSIL), cervical intrae-
pithelial neoplasia grade 1, 2 or 3 (CIN1, 2 or 3) and cer-
vical cancer. The histological diagnosis of each case was
reviewed by an experienced pathologist who was un-
aware of the HPV testing results.
Mann-Whitney, Fisher exact and linear by linear asso-
ciation tests were used for comparisons between AA and
E lineages. Variables affecting cervical cancer risk were
analyzed by a logistic regression model. All statistical




Ninety-seven (97/170 = 57.1%) E6, 165 (165/170 = 97.1%)
E7, 74 (74/170 = 43.5%) entire L1 and 90 (90/170 =
52.9%) partial L1 sequences from HPV18 isolates were
successfully amplified by PCR and sequenced. In total,
only 97 samples (E6-E7-L1 sequences) could be classified
as lineages and sublineages according to E6-E7
sequence-based historical nomenclature rules of previ-
ous studies [9, 10].
The genetic analysis of the regions of the 97 samples is
shown in Fig. 1. They were composed of 26 intact and 10
partial E6-E7-L1 sequences (BRM01 ~ 36 variants). In
total, we found 44 nucleotide substitutions. Among them,
29 nucleotide substitutions were already reported: T104C,
A171G, T173G, C287G, A482C, T485C, C549A, C554T,
C751T, C860T, C5478T, A5497G, G5609A, T5619A,
C5701G, C5875A, C5920T, A6059G, T6131G, T6146G,
A6401G, A6430C, A6441C, C6460G, C6625G, C6842G,
A6970G, and G7032A [11–14, 17, 18, 24, 26–29], and 15
nucleotide substitutions were newly identified: C158T of
BRM05, T317G of BRM07, T443G of BRM08, A560G of
BRM10, A5467G of BRM12, A5560C of BRM16, A5678C
of BRM17, A6155G of BRM21, G6462A of BRM22,
T6650G of BRM23, G6701A of BRM24, T6809C of
BRM26, A6823G of BRM27, T6941C of BRM28, and
T6953C of BRM36. Among the 15 new nucleotide substi-
tutions, 6 nonsynonymous amino acid substitutions were
at positions 317, 443, 5467, 5560, 6462, and 6823 (F71L
and N113K in E6; H13R, H44P, A345T, and N465S in L1,
respectively). In addition, all the 15 newly identified se-
quences in this study were submitted to GenBank under
the accession numbers MK813921-MK813935 (Fig. 1).
The phylogenetic tree analysis was performed using
the E6-E7-L1 genes of the 97 Korean HPV18 isolates
and 28 already reported variants (Fig. 2). According to
the E6-E7 sequence-based previous nomenclature rule
[10, 11], all the previous AA lineages (BRM01 ~ 28, total
89 samples) were matched updated A1 sublineage se-
quences. However, except for one A4 sublineage
(BRM32, 1 sample), the other seven variants (BRM29 ~
Table 1 Primers used for PCR amplification and sequence analysis
Gene Primer Trial Primer sequence (5′-3′) Position Size Success rate Ref
E6 E6-a-F 1 AGAAACACACCACAATACTATGGCG 86 661 86/170 [21]
E6-a-R GTCGGGCTGGTAAATGTTGAT 746
E6-b-F 2 GGGACCGAAAACGGTGTAT 55 611 11/79 [22]
E6-b-R GAAGGTCAACCGGAATTTCA 665
E6-c-F 3 GGGACCGAAAACGGTGTAT 55 557 0/68 [22]
E6-c-R ATGTTGCCTTAGGCTCCATGC 611
E7 E7-a-F 1 CGACAGGAACGACTCCAACGA 540 431 165/170 [21]
E7-a-R ATAAAACCAGCCGTTACAACCCGTG 970
L1 L1–1-a-F 1 GTAACGGTCCCTTTAACCTCCTC 5402 650 153/170 [21]
L1–1-a-R CATTGTCCCTAACGTCCTCAG 6051
L1–2-a-F AAGTTCCCATGCCGCCACGTCTAAT 6002 505 162/170
L1–2-a-R AGAGCCACTTGGAGAGGGAGAATAC 6506
L1–3-a-F GCTCTATTGTTACCTCTGACTCC 6502 636 32/170
L1–3-a-R ATTACTTCCTGGCACGTACACGCAC 7137
L1–3-b-F 2 AGTTATGTATTTTGGGCTGTG 6077 756 0/128 [10]
L1–3-b-R ACACCAAAGTTCCAATCCTCTAA 6832
L1–3-b’-F AGTATAGCAGACATGTTGAGGAA 6699 551 0/128
L1–3-b’-R CATACAACATACAACAACAACCAT 7249
L1–3-c-F 3 TCCCTCTCCAAGTGGCTCTA 6488 601 44/128 [22]
L1–3-c-R AGTGGCAGATGGAGCAGAAC 7088
Abbreviation: Ref reference
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31 and 33 ~ 36, total 8 samples) of the previous E lineage
did not match the reported sublineages (Figs. 1, 2).
Association between HPV18 variants and cervical lesion
severity
All 97 of the women underwent pathological examina-
tions, pap smears (cytological) and/or cervical biopsies
(histological) after HPV genotyping within 3months.
The cervical pathologic results were classified as normal
in 25 women (25/97 = 25.8%); ASCUS in 7 (7/97 = 7.2%);
LSIL/CIN 1 in 35 (35/97 = 36.1%); HSIL/CIN2 and 3 in
18 (18/97 = 18.6%); and carcinoma in 12 (12/97 = 12.4%).
There was no statistically significant association between
HPV18 lineage and cervical lesion severity (Table 2).
Most women underwent HPV genotyping several
times; 23 were found to have a different types of HPV
infection, aside from type 18, in their lifetime. In par-
ticular, 17 women had an infectious history of other
high-risk HPVs, including types 16, 31, 33, 35, 39, 45,
51, 52, 58, or 59, as diagnosed according to the Inter-
national Agency for Research on Cancer (IARC) [30].
There was no association between HPV18 lineages and
other types of HPV co-infection (Table 2). Additional in-
fections by other types are not related to the develop-
ment of cancer (data not shown).
Of the 97 women involved in this study, 54 women
underwent an additional follow-up pathological evalu-
ation. Twenty-two women had worsening lesions con-
firmed by serial pathological tests. There was no
association between HPV18 lineages and disease pro-
gression (P = .773) (Table 2).
Discussion
From 2010 to 2017, almost half (49.1%) of requested cer-
vical HPV genotyping tests were positive for any type of
HPV in a secondary referral hospital in Seoul, Korea.
Among the positive results, the frequency of HPV 18
single positive was 4.2%. The frequency of the present
study was comparable to other reports in Korea (total
HPV prevalence was 16.7% ~ 40.7%, and the HPV 18
prevalence among HPV-positive women was 0.5% ~
3.6%) [31–33].
Fig. 1 Nucleotide sequence variations in the HPV E6-E7-L1 isolates in Korean women. *Previously reported: N, No †Grade of cervical lesions: ①
Normal, ② ASCUS, ③ LSIL/CIN1, ④ HSIL/CIN2 and 3, ⑤ Cancer ‡L1 secondary structure: H, helix; C, coil; S, strand Abbreviations: AA, Asian-
Amerindian; E, European; ASCUS, Atypical squamous cells of undetermined significance; LSIL, Low-grade squamous intraepithelial lesion; HSIL,
High-grade squamous intraepithelial lesion; CIN, Cervical intraepithelial neoplasia; na, not assessed; aa, amino acid. E6, E7 and L1 nucleotide
positions at which variations were observed are written vertically across the top. Amino acid translations and immunodominant loop structures of
L1 are shown at the bottom. The GenBank accession numbers of the newly discovered sequences are on the left. The phylogenetic groupings
based on the analysis of E6-E7 are indicated. For each variant sequence, the positions that do not vary relative to the HPV reference are marked
with a blank. The regions where sequencing failed are marked with an X. The cervical lesion grade for each variant is shown on the right
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The distributions of HPV variants differ among geo-
graphic origins, evolutionary dynamics, and pathogen-
icity. In our population, 6 substitutions, namely, C287G
in E6 and G5503A, C5701G, C6460G, C6625G, and
C6842G in L1, were found in all HPV18 variants. These
6 substitutions were also found in all HPV18 isolates in
southeastern and northeastern China [11, 18], which
Korea is located next to, but found in 40% of HPV 18 in
southwest and central China [24]. These findings sup-
port the geographical distribution of HPV lineages.
We previously discovered that the HPV 16 variants
were composed of A1 ~ 3, A4, C, and D sublineages
(54.1, 37.8, 0.7, and 7.4% of samples, respectively) in
Korea [21]. Upon comparing HPV 16, little diversity was
evident, indicating that previous lineages AA and E com-
prised 91.7 and 8.3%, respectively, in Korean HPV 18.
Previous studies reported that the risk of developing
high-grade CIN is significantly increased with the
non-European variants [13, 34]. One study [35] re-
ported that the AA and European variants had signifi-
cantly higher associations with pre-invasive lesions
than the African variants. In contrast, other studies
showed that no significant difference in pre-invasive
lesion risk was observed between the variant lineages
(A, B, and C) [14, 17, 26]. Our results are in line with
the latter conclusion; there was no statistically signifi-
cant association between HPV18 lineages and cervical
pathologic lesions in Korea.
Fig. 2 Phylogenetic tree of the HPV18 variants by the Maximum Likelihood method. The evolutionary history was inferred using the Maximum
Likelihood method with 1000 bootstraps in a Tamura-Nei model. All positions with less than 95% site coverage were eliminated; i.e., fewer than
5% alignment gaps, missing data, and ambiguous bases were allowed at any position (partial deletion option). Numbers near the line indicate
bootstrap values. Evolutionary analyses were conducted in MEGA X
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In the aspect of public health, many countries have
implemented national policies of HPV vaccination. In
Korea, HPV vaccination has been free for 12-year-old
girls since 2016, and the government intends to expand
the vaccination targets. Three prophylactic vaccines have
received licensure from Korea Food and Drug Adminis-
tration: the AS04-adjuvanted bivalent (HPV16/18) vac-
cine (Cervarix®, GlaxoSmithKline, Belgium), which was
licensed in 2008; the aluminum hydroxyphosphate sulfate
(AAHS) adjuvant quadrivalent (HPV6/11/16/18) vaccine
(Gardasil®, Merck, US), which was licensed in 2007; and
the AAHS adjuvant 9-valent (HPV6/11/16/18/31/33/45/
52/58) vaccine (Gardasil®9, Merck, US), which was li-
censed in 2016. These prophylactic HPV vaccines are
composed of L1 proteins of multiple HPV combinations
[5, 7]. The loop structures of the HPV L1 major capsid
protein contribute to the epitopes of vaccine-induced
cross-neutralizing antibodies. Therefore, amino acid
changes in the L1 loop region could be a critical issue for
vaccination development. Our data on the genetic diver-
sity of the HPV18 variants in Korea show two
nonsynonymous substitutions in the loop structures,
L64M within the BC loop (of BRM34) and T149N within
the DE loop (of BRM20, BRM31 ~ 36). It may be helpful
to design second-generation prophylactic HPV vaccines
and implement feasible nationwide vaccination programs.
With the development of next-generation sequencing
(NGS), the whole-genome sequencing (WGS) of 8 kb
HPV became easier, making the analysis of lineages and
single-nucleotide polymorphisms (SNPs) relatively faster
and more accurate. However, WGS analysis pipelines in
microbiological fields have not yet been established sys-
tematically, and it is difficult to analyze multiple samples
with limited resources. In addition, although WGS iden-
tifies more variants and contributes to the construction
of more accurate phylogenetic trees than partial sequen-
cing, the data composed of E6-E7-L1 sequences over the
past 20 years does not have significantly reduced reliabil-
ity compared to WGS. Thus far, many studies have been
selectively conducted on the oncogenic proteins E6 and
E7, and the major capsid protein L1 plays an important
role in the prophylactic vaccine, as our study suggests.
Table 2 Distribution and statistical comparison of HPV18 lineages between the AA and E lineages
AA(n = 89) E(n = 8) P value
Age, years 46 (40–54) 58 (47–63) 0.344*
Cervical lesion, n Grouping
Normal ① 22 (24.7%) 3 (37.5%) 0.298†
ASCUS ② 5 (5.6%) 2 (25.0%)
LSIL/CIN1 ③ 34 (38.2%) 1 (12.5%)
HSIL/CIN2&3 ④ 17 (19.1%) 1 (12.5%)
Cancer ⑤ 11 (12.4%) 1 (12.5%)
Pathology and treatment, n
Cancer ⑤ 11 (12.4%) 1 (12.5%) 1.000‡
Non-cancer ① +② +③ +④ 78 (87.6%) 7 (87.5%)
Surgery ④ +⑤ 28 (31.5%) 2 (25.0%) 1.000‡
Observation ① +② +③ 61 (68.5%) 6 (75.0%)
Definite dysplasia ③ +④ +⑤ 62 (69.7%) 3 (37.5%) 0.110‡
Normal and ASCUS ① +② 27 (30.3%) 5 (62.5%)
Evidence of co-infection, n
With other risk type(s) 21 (23.6%) 2 (25.0%) 1.000‡
With other high-risk type(s) 16 (18.0%) 1 (12.5%) 1.000‡
§Serial follow-up testing (n = 54)
Progression (n) n = 50 n = 4
Progression 21 (42.0%) 1 (25.0%) 0.773‡
No progression 29 (58.0%) 3 (75.0%)
* Mann-Whitney test
† Linear by linear association
‡ Fisher’s exact test
§ 54 out of 97 patients underwent serial pathological examinations
Grouping: ① Normal, ② ASCUS, ③ LSIL/CIN1, ④ HSIL/CIN2 and 3, ⑤ Cancer
Abbreviation: AA Asian-Amerindian; E European; ASCUS Atypical squamous cells of undetermined significance; LSIL Low-grade squamous intraepithelial lesion; HSIL
High-grade squamous intraepithelial lesion; CIN Cervical intraepithelial neoplasia
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Conclusions
In summary, this research identified 15 new nucleotide
substitutions and is the first to analyze the distribution of
HPV18 variants in Korean women and to match the re-
sults to pathologic results. Data regarding the geographic/
ethnic HPV18 genetic diversity distributions may be help-
ful for designing diagnostic probes, correlating epidemio-
logic cervical cancer risks, and analyzing the efficacy of
HPV vaccines for targeted populations in Korea.
Abbreviations
AA: Asian-Amerindian; AAHS: Aluminum hydroxyphosphate sulfate;
AFR: African; ASCUS: Atypical squamous cells of undermined significance;
CIN: Cervical intraepithelial neoplasia; E: European; E: Early gene; HPV: Human
papillomavirus; HSIL: High-grade squamous intraepithelial lesion;
IARC: International Agency for Research on Cancer; LSIL: Low-grade
squamous intraepithelial lesion; L: Late gene; LCR: Long control region;
NGS: Next-generation sequencing; SNP: Single-nucleotide polymorphism;





NK and SS: Study concept and design; NK and JEK: Performed the
experiments; NK, JSP, and JEK: Acquisition of data; NK and SS: Analysis and
interpretation of data; NK and SS: Drafting of the manuscript; JHP, HP, EYR,
and JHY: Critical revision of the manuscript for important intellectual content;




Availability of data and materials
The datasets used and/or analyzed during the current study are available
from the corresponding author on reasonable request.
Ethics approval and consent to participate
This study was approved by the Institutional Review Board of Seoul National




The authors declare that they have no competing interests.
Author details
1Department of Laboratory Medicine, Seoul National University Metropolitan
Government Boramae Medical Center, Seoul, South Korea. 2Department of
Laboratory Medicine, Seoul National University College of Medicine, Seoul,
South Korea. 3Department of Laboratory Medicine, Seoul National University
Bundang Hospital, Gyeonggi-do, South Korea. 4Department of Pathology,
Seoul National University Metropolitan Government Boramae Medical Center,
Seoul, South Korea. 5Department of Pathology, Seoul National University
College of Medicine, Seoul, South Korea. 6Department of Laboratory
Medicine, Seoul National University Hospital, Seoul, South Korea.
Received: 5 February 2020 Accepted: 7 May 2020
References
1. WHO Global Cancer Observatory [Available from: https://gco.iarc.fr/].
2. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human
papillomavirus type distribution in invasive cervical cancer and high-grade
cervical lesions: a meta-analysis update. Int J Cancer. 2007;121(3):621–32.
3. Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D,
et al. Against which human papillomavirus types shall we vaccinate and
screen? The international perspective. Int J Cancer. 2004;111(2):278–85.
4. Bernard HU. Taxonomy and phylogeny of papillomaviruses: an overview
and recent developments. Infect Genet Evol. 2013;18:357–61.
5. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major
capsid protein self-assembles into virus-like particles that are highly
immunogenic. Proc Natl Acad Sci. 1992;89(24):12180–4.
6. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, et al. The biology
and life-cycle of human papillomaviruses. Vaccine. 2012;30(Suppl 5):F55–70.
7. Bissett SL, Godi A, Beddows S. The DE and FG loops of the HPV major
capsid protein contribute to the epitopes of vaccine-induced cross-
neutralising antibodies. Sci Rep. 2016;6:39730.
8. Shen-Gunther J, Cai H, Zhang H, Wang Y. Abundance of HPV L1 Intra-
Genotype Variants With Capsid Epitopic Modifications Found Within Low-
and High-Grade Pap Smears With Potential Implications for Vaccinology.
Front Genet. 2019;10:489.
9. Chabeda A, Yanez RJR, Lamprecht R, Meyers AE, Rybicki EP, Hitzeroth II.
Therapeutic vaccines for high-risk HPV-associated diseases. Papillomavirus
Res(Amsterdam, Netherlands). 2018;5:46–58.
10. Ong CK, Chan SY, Campo MS, Fujinaga K, Mavromara-Nazos P, Labropoulou
V, et al. Evolution of human papillomavirus type 18: an ancient
phylogenetic root in Africa and intratype diversity reflect coevolution with
human ethnic groups. J Virol. 1993;67(11):6424–31.
11. Sun Z, Liu J, Wang G, Zhou W, Liu C, Ruan Q. Variant lineages of human
papillomavirus type 18 in Northeast China populations characterized by
sequence analysis of E6, E7, and L1 regions. Int J Gynecol Cancer. 2012;
22(6):930–6.
12. Schlecht NF, Burk RD, Palefsky JM, Minkoff H, Xue X, Massad LS, et al.
Variants of human papillomaviruses 16 and 18 and their natural history in
human immunodeficiency virus-positive women. J Gen Virol. 2005;86(10):
2709–20.
13. Arroyo SL, Basaras M, Arrese E, Hernáez S, Andía D, Esteban V, et al. Human
papillomavirus (HPV) genotype 18 variants in patients with clinical
manifestations of HPV related infections in Bilbao, Spain. Virology J. 2012;9:
258.
14. Chen AA, Gheit T, Franceschi S, Tommasino M, Clifford GM. Human
papillomavirus 18 genetic variation and cervical cancer risk worldwide. J
Virol. 2015;89(20):10680–7.
15. Chen Z, Schiffman M, Herrero R, DeSalle R, Anastos K, Segondy M, et al.
Evolution and taxonomic classification of alphapapillomavirus 7 complete
genomes: HPV18, HPV39, HPV45, HPV59, HPV68 and HPV70. PLoS One. 2013;
8(8):e72565.
16. Burk RD, Harari A, Chen Z. Human papillomavirus genome variants. Virology.
2013;445(1–2):232–43.
17. Chen Z, DeSalle R, Schiffman M, Herrero R, Burk RD. Evolutionary dynamics
of variant genomes of human papillomavirus types 18, 45, and 97. J Virol.
2009;83(3):1443–55.
18. Xu HH, Zheng LZ, Lin AF, Dong SS, Chai ZY, Yan WH. Human papillomavirus
(HPV) 18 genetic variants and cervical cancer risk in Taizhou area. China
Gene. 2018;647:192–7.
19. Sait K, Turki R, Abuzenadah AM, Jiffiri OH, Bohmaidah A, Sohrab SS. Genetic
diversity and phylogenetic analysis of HPV 16 & 18 variants isolated from cervical
specimens of women in Saudi Arabia. Saudi J Biol Sci. 2019;26(2):317–24.
20. Frati E, Bianchi S, Amendola A, Colzani D, Petrelli F, Zehender G, et al.
Genetic characterization of variants of HPV-16, HPV-18 and HPV-52
circulating in Italy among general and high-risk populations. Mol Med Rep.
2019;21:894.
21. Park JS, Shin S, Kim EC, Kim JE, Kim YB, Oh S, et al. Association of human
papillomavirus type 16 and its genetic variants with cervical lesion in Korea.
APMIS. 2016;124(11):950–7.
22. Hall BG. Building phylogenetic trees from molecular data with MEGA. Mol
Biol Evol. 2013;30(5):1229–35.
23. Kumar S, Stecher G, Li M, Knyaz C, Tamura K, MEGA X. Molecular
evolutionary genetics analysis across computing platforms. Mol Biol Evol.
2018;35(6):1547–9.
24. Shen M, Ding X, Li T, Chen G, Zhou X. Sequence variation analysis of HPV-
18 isolates in southwest China. PloS one. 2013;8(2):e56614.
25. Untergasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, Remm M, et al.
Primer3--new capabilities and interfaces. Nucleic acids research. 2012;40(15):
e115-e. [Available from: http://bioinfo.ut.ee/primer3-0.4.0/].
Kim et al. Virology Journal           (2020) 17:70 Page 7 of 8
26. Arias-Pulido H, Peyton CL, Torrez-Martinez N, Anderson DN, Wheeler CM.
Human papillomavirus type 18 variant lineages in United States populations
characterized by sequence analysis of LCR-E6, E2, and L1 regions. Virology.
2005;338(1):22–34.
27. Sichero L, Ferreira S, Trottier H, Duarte-Franco E, Ferenczy A, Franco EL, et al.
High grade cervical lesions are caused preferentially by non-European
variants of HPVs 16 and 18. Int J Cancer. 2007;120(8):1763–8.
28. Liu Y, Pan Y, Gao W, Ke Y, Lu Z. Whole-genome analysis of human
papillomavirus types 16, 18, and 58 isolated from cervical Precancer and
Cancer samples in Chinese women. Sci Rep. 2017;7(1):263.
29. van der Weele P, Meijer CJLM, King AJ. High whole-genome sequence
diversity of human papillomavirus type 18 isolates. Viruses. 2018;10(2):68.
30. IARC 2019 [Available from: https://monographs.iarc.fr/agents-classified-by-
the-iarc/].
31. So KA, Hong JH, Lee JK. Human papillomavirus prevalence and type
distribution among 968 women in South Korea. J Cancer Prev. 2016;21(2):
104–9.
32. Lee EH, Um TH, Chi H-S, Hong Y-J, Cha YJ. Prevalence and distribution of
human papillomavirus infection in Korean women as determined by
restriction fragment mass polymorphism assay. J Korean Med Sci. 2012;
27(9):1091–7.
33. Nah EH, Cho S, Kim S, Cho HI. Human papillomavirus genotype distribution
among 18,815 women in 13 Korean cities and relationship with cervical
cytology findings. Ann Laboratory Med. 2017;37(5):426–33.
34. Villa LL, Sichero L, Rahal P, Caballero O, Ferenczy A, Rohan T, et al. Molecular
variants of human papillomavirus types 16 and 18 preferentially associated
with cervical neoplasia. J General Virol. 2000;81(Pt 12):2959–68.
35. Xi LF, Koutsky LA, Hildesheim A, Galloway DA, Wheeler CM, Winer RL, et al.
Risk for high-grade cervical intraepithelial neoplasia associated with variants
of human papillomavirus types 16 and 18. Cancer Epidemiol Biomarkers
Prev. 2007;16(1):4–10.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Kim et al. Virology Journal           (2020) 17:70 Page 8 of 8
